Examines how stimulation and medication impact beta-band power in Parkinson's disease, suggesting implications for adaptive deep brain stimulation.
The spectral characteristics of STN beta oscillations and their performance as a biomarker in aDBS for Parkinson's disease are influenced by the stimulation and medication conditions in which it is implemented.
No takes yet. Share an insight, caveat, or question.
Hammer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: